Facebook Twitter LinkedIn Google Plus RSS

PCT, ImmunoCellular announce manufacturing partnership

By ,

New York-based NeoStem Inc.; its Allendale-based subsidiary, Progenitor Cell Therapy LLC; and ImmunoCellular Therapeutics Ltd., of Los Angeles, a clinical-stage biotechnology company developing cancer therapies, announced today PCT will provide manufacturing services to support research and development of an ImmunoCellular drug candidate.

Financial terms were not disclosed. PCT provides manufacturing services for ImmunoCellular's lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma.

Also Popular on NJBIZ

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment


Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy